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OBJECTIVE: An estimated 1.25 million Americans are chroni-
cally infected with hepatitis B virus, many of whom develop
severe and potentially fatal liver diseases. Despite the high preva-
lence and serious health consequences, little is about the impact
on quality of life of disease states resulting from chronic HBV
infection. The objective was to estimate preferences (ratings and
utility weights) for six hepatitis B-related disease states among
infected persons. METHODS: Utility weights for six disease-
related health states were elicited from a sample of 56 patients
chronically infected with HBV in San Francisco using a standard
gamble. Probability wheels with 2-color pie charts for the rela-
tive probabilities of perfect health and death were employed as
props. RESULTS: The mean age was 51y (standard deviation:
12, range: 20 to 77y) and 77% were men. Mean utilities were:
0.72 (95% conﬁdence interval: 0.68; 0.79) for chronic hepatitis
B; 0.70 (0.65; 0.77) for compensated cirrhosis; 0.42 (0.35; 0.47)
for decompensated cirrhosis; 0.48 (CI: 0.40; 0.52) for hepato-
cellular carcinoma; 0.62 (0.56; 0.67) in the ﬁrst year after liver
transplant; and 0.72 (0.65; 0.77) after ﬁrst year post-transplant.
CONCLUSION: These utility values, the ﬁrst published on
patients in the United States, indicate that health states resulting
from chronic HBV infection substantially lower patients’ quality-
of-life. These preferences (utility weights) for health states can
be incorporated into many aspects of medical decision making,
including summary measures of health related quality of life,
monitoring population health, bedside clinical decision making,
and in technology assessment. For all health states, the utilities
collected here were lower than published estimates that are based
on clinicians opinion.
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OBJECTIVE: Although the incidence of the hepatitis B virus in
the UK is low, persons with chronic infection can develop severe
and potentially fatal liver diseases. The objective was to estimate
preferences (ratings and utility weights) for six hepatitis B-related
disease states among uninfected and infected persons.
METHODS: Three hepatologists characterized the typical effects
of symptoms on health-related quality of life. Standard gamble
(SG) utility weights for six disease-related health states were
elicited from a sample of 100 uninfected persons and 87 patients
chronically infected with HBV in the UK. Probability wheels
with 2-color pie charts for the relative probabilities of perfect
health and death were used as props. RESULTS: The mean age
of patients was 43y and 46y for uninfected persons; and 57%
and 47% were men, respectively. For patients and uninfected
persons, respectively, mean SG utilities were: 0.77 (95% conﬁ-
dence interval: 0.71; 0.81) and 0.82 (0.78, 0.85); for chronic
hepatitis B; 0.73 (0.65, 0.77) and 0.83 (0.80, 0.87) for compen-
sated cirrhosis; 0.34 (0.25, 0.39) and 0.36 (0.30, 0.42) for
decompensated cirrhosis; 0.36 (0.28, 0.41) and 0.46 (0.39, 0.52)
for hepatocellular carcinoma; 0.56 (0.49, 0.62) and 0.71 (0.65,
0.76) in the ﬁrst year after liver transplant; and 0.67 (0.59, 0.73)
and 0.82 (0.78, 0.86) after ﬁrst year post-transplant. CON-
CLUSION: These utility values, the ﬁrst published on patients
or uninfected persons in the UK, indicate that health states result-
ing from chronic HBV infection substantially lower patients’
quality-of-life. The mean SG utilities were systematically lower
for infected than for uninfected persons. These preferences for
health states can be incorporated into many aspects of medical
decision making, including summary measures of health related
quality of life, monitoring population health, bedside clinical
decision making, and in technology assessment.
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OBJECTIVES: To compare the direct health costs of HIV-
positive patients reporting sub-optimal intake of antiretroviral
therapy (ART) with those of patients reporting full adherence.
METHODS: 546 subjects from the Italian multicenter observa-
tional study ICoNA (Italian Cohort Naive Antiretrovirals) were
followed between 1997 and 2004. Non-adherence to ART was
assessed by a self-administered questionnaire. Medical costs
incurred by the National Health Service were calculated retro-
spectively as from ﬁrst ART and expressed in constant 1997
prices. RESULTS: Mean time on ART was 5.75 years (range
1.04–7.77); mean HIV-RNA and CD4 cells at baseline were 4.75
log10 copies/ml (range 1.3–6.6) and 307/ml (range 0–1309). Non-
adherence was reported by 197 (36%) patients, who showed a
higher number of new AIDS-deﬁning events (p = 0.01), of
detectable viremia episodes (p < 0.001), and of ART changes 
(p = 0.01). Overall medical costs and ART costs per year were
on average €6392 (range €555–€42,183) and €5373 (range
€537–€35,582), respectively, and did not signiﬁcantly differ
between the two groups. Annual inpatient costs were higher in
the non-adherent group (€432; 95%CI €256–€608) than in the
adherent group (€198; 95%CI €127–€269; p < 0.005). On mul-
tivariate linear regression, higher HIV-RNA, lower nadir and
baseline CD4, fewer ART changes, and interaction between low
adherence and number of therapy switches were independently
associated with higher log-transformed ART costs per year.
Older age, HCV co-infection, sub-optimal ART adherence, lower
CD4 nadir, and higher baseline CD4 were independently associ-
ated with higher annual inpatient costs, based on multivariate
tobit analysis. CONCLUSIONS: Non-adherence is common
among HIV-positive patients and is associated with virological
failure, disease progression, more frequent hospitalizations 
and treatment changes. Total and ART costs do not seem to be
signiﬁcantly affected by non-adherence, probably because of
switches to simpler and less expensive treatment options,
whereas inpatient costs are signiﬁcantly increased by sub-optimal
drug intake.
PIN17
COST-EFFECTIVENESS ANALYSIS OF ENFUVIRTIDE ADDED
TO AN OPTIMISED THERAPY VS.AN OPTIMISED THERAPY
ALONE IN PATIENTS WITH H.I.V./AIDS
Serrano D1, Badia X1, Álvarez Sanz C2, García Pulgar M3,
Green J4
1Health Outcomes Research Europe Group, Barcelona, Cataluña,
Spain; 2Roche Farma S.A, Madrid, Spain; 3Roche Farma S.A, Madrid,
Madrid, Spain; 4Hoffmann-La Roche Inc, Nutley, NJ, USA
OBJECTIVE: To analyse the efﬁciency of adding Enfuvirtide
(ENF) to an Optimised Therapy (OT) in HIV patients who are
